




University of
St Andrews

Mitochondrial targets for multi-target ligand design

Rona R. Ramsay,

Amelia Hunter, Gayle H. Doherty

*Biomedical Sciences Research Complex, University of St Andrews,
North Haugh, St Andrews KY16 9ST, UK*



University of
St Andrews




Outline

Why we look for targets to protect mitochondrial function

- Mitochondrial enzymes such as MAO are targets for treatment of neuropathology
- Some MAOI protect mitochondrial function
- Mitochondria interact with the rest of the cell and movement, fusion, and fission are vital to cell survival
- Compromised mitochondrial function leads to cell death, e.g., permeant cations are accumulated – can interfere with ATP production


Many structures inhibit MAO B reversibly

Safinamide
Binda et al. 2007



B, 450 nM

(2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl] methylamino]propanamide



Desideri et al. 2016

B, 11 nM


(E)-5,7-Dichloro-3-([(2-dimethylamino)pyrimidin-5-yl]methylene)-chroman-4-one

Designed inhibition

OR

Unintended inhibition


Mazouz et al. 1993



B, 1.1 nM

5-(4-benzyloxyphenyl)-3-(2-hydroxyethyl)-1,3,4-oxadiazol-2(3H)-one

A, 11 nM




Petzer et al. 2012

Azure B: R = CH₃

B, 960 nM





Pioglitazone (anti-diabetic)



B, 500 nM


(RS)-5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)thiazolidine-2,4-dione

Successful MAO drugs inhibit irreversibly

Chemical type	Example	Structure	Drug name	Selectivity	Inhibition type
Hydrazine	Phenylzine 2-phenylethylhydrazine		Nardil	both	Irreversible <i>flavin N5</i>
Acetylenic	Clorgyline N-(3-(2,4-dichlorophenoxy)propyl)-N-methylprop-2-yn-1-amine		Clorgyline	A	Irreversible <i>flavin N5</i>
Acetylenic	Deprenyl (R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine		Selegiline	B	Irreversible <i>flavin N5</i>
Cyclopropylamine	Tranlycypromine (1R,2S)-2-phenylcyclopropanamine		Pamate	B>A	Irreversible <i>flavin C4a</i>

Why inhibit MAO, and which form ?

MAO oxidises neurotransmitters and scavenges biogenic amines




Assessing MAO inhibition – caution !

- Enzyme: rat and human MAO differ
- Substrates: MAO A and B have different K_m values for all the common substrates
- IC_{50} value varies with the substrate concentration
- In the coupled assay, beware inhibition of horseradish peroxidase
- There are two forms of the enzyme that can bind inhibitor: oxidized and reduced. The two forms have different affinities for ligands
- Definitive parameter for reversible inhibition is K_i , BUT for irreversible inhibition there is a time factor, so need K_i and k_{inact}


Reversible inhibition e.g. 2

Kinetics, computation and spectroscopy show origin of specificity


Selectivity



Binding Mode






Spectral Changes




Juárez-Jiménez et al (2014) **Biochim. Biophys. Acta 1844: 389–397** Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: Role of Asn181 and Ile335 validated by spectroscopic and computational studies.

Type of spectral change depends on the end group and this permits determination of the orientation of oxazolidinones in MAO A



- 1 -NHCOCH₃
- 2 -OH
- 3 -NH₂






Orientation of oxazolidinones in MAO A

Jones et al., 2005



Oxa molecules with small terminal groups can orient in either direction:



So test inhibition by double-ended molecules:



$IC_{50} = 90 \text{ uM}$



$IC_{50} = 0.5 \text{ uM}$

Compare reversible binding with inactivation

	μM	nM		
	Reversible	Irreversible		
	K_i (μM)	IC_{50} (nM)		
	MAO A	MAO A	MAO B	$\text{IC}_{50}\text{B}/\text{IC}_{50}\text{A}$
ASS234	0.053 ± 0.013	0.17 ± 0.03	15830 ± 1040	93118
Clorgyline	0.014 ± 0.001	0.42 ± 0.08	10660 ± 953	25380
PF9601N	25 ± 5	790 ± 105	11 ± 2	0.0139
L-Deprenyl	75 ± 11	630 ± 86	3.0 ± 0.9	0.0048
Tranylcypromine	6.7 ± 0.5	237 ± 61	73.5 ± 4.9	3.2

K_i : Reversible inhibition


IC_{50} : Activity was measured after 30 minutes incubation with the inhibitor using 1 mM tyramine as substrate for both MAO A and MAO B.

Outline

Why we look for targets to protect mitochondrial function



- Mitochondrial enzymes such as MAO are targets for treatment of neuropathology
- Mitochondria interact with the rest of the cell and movement, fusion, and fission are vital to cell survival
- Compromised mitochondrial function leads to cell death, e.g., permeant cations are accumulated – can interfere with ATP production
- Some MAOI protect mitochondrial function




Mito: 0.2 of liver cell volume
(0.5 of heart cell volume)
Williams et al. PNAS 110, 10479–10486

(Richard Clark)

Mitochondria interact with the cytosol

cytoskeleton




VDAC pull-down


Messina et al (2014) Mol. BioSyst. 10, 2134--2145

VDAC interactome: pathways and diseases

Disease associations



Role in cell



New experiments

(not published so data deleted)

- Seahorse Analyser

Measured oxygen consumption and ATP generation in SY5Y cells before and after full differentiation into neuronal cells: MAOI protect against loss of bioenergetic function. (Mechanism unrelated to MAO inhibition?)

- HCA stress

decreased cell viability, increased ROS production, increased stressed morphology, increased MFN1 and FIS1: clorgyline and tranylcypromine effects differ

Acknowledgements

Docking, data mining, MD

F. Javier Luque, Spain

Biology

Angela Messina, Italy

Vito De Pinto, Italy

Darrell Mousseau, Canada

Mass spectrometry

St Andrews Mass Spectrometry Facility, funded by the Wellcome Trust.

Chemistry

Claudia Binda, Italy

Maria Carreiras, Portugal

Jose Marco-Contelles, Spain

Alen Albreht, Slovenia

Irene Vovk, Slovenia